Global Cellular Therapy in Oncology Market
Global Cellular Therapy in Oncology Market

Cellular Therapy in Oncology Comprehensive Study by Type (Consumables, Equipment (Cell Processing Equipment, Single-use Equipment), Systems & Software), Technology (Bioreactor, Cell Immortalization Technology, Controlflow centrifugation, Ultrasonic Lysis, Lyophilization, Electrodspinning, Viral Vector Technology, Genome Editing Technology), End Use (Hospitals, Specialty Clinics), Cell (T-cells, Stem Cells, Others) Players and Region - Global Market Outlook to 2026

Cellular Therapy in Oncology Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 209 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Cellular Therapy in Oncology Market Scope
Cancer treatment has generally consisted of a mix of surgery, radiation, and chemotherapy in recent decades. Although survival rates have improved and relapse rates have reduced for most malignancies over the last several decades, the efficacy of these therapies varies significantly in response to a variety of variables. However, the scientific and medical societies have acknowledged that there is a large unmet need for more effective cancer medicines, particularly for patients with advanced malignancies who have failed to react to standard treatments. Engineered cells are a new age of targeted cancer therapy that has been viewed as a viable therapeutic possibility by experts. Engineered cell treatment (a mix of gene and cell therapy) as part of cancer targeted therapy might be a useful tool. T-Cell engineering has shown positive outcomes, whereas MSC engineering is in the early stages of development.

The Cellular Therapy in Oncology market study is segmented by Type (Consumables, Equipment (Cell Processing Equipment, Single-use Equipment) and Systems & Software) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States & Germany Players will contribute to the maximum growth of Global Cellular Therapy in Oncology market throughout the predicted period.

Thermo Fisher Scientific Inc. (United States), MaxCyte (United States), Danaher Corporation (United States), Merck KGaA (Germany), Becton, Dickinson and Company (United States), Lonza Group (Switzerland), Fresenius Medical Care AG & Co. KGaA (Germany), Bio-Techne Corporation (United States), Sartorius AG (Germany) and Terumo BCT (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Avantor, Inc. (United States), RoosterBio Inc. (United States), SIRION Biotech GmbH (Germany), CellGenix GmbH (Germany), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada) and IxCells Biotechnology (China).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Cellular Therapy in Oncology market by Type, Application and Region.

On the basis of geography, the market of Cellular Therapy in Oncology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies

On 5th February, 2021 - Bristol Myers Received FDA Approval for Cancer Cell Therapy “Breyanzi”. Breyanzi, Formerly Known as Liso-Cel, Is Used by People with Specific Kinds of Large B-Cell Lymphoma Who Have Had At Least Two Prior Therapies and Whose Disease Has Progressed. and On 5th February, 2020 - GIOSTAR (Global Institute of Stem Cell Therapy and Research) Launched Stem Cell / Cancer Research and Therapy Center in India. The Facility Is the Latest Milestone in GIOSTAR's Global Development In India, Mexico, The United States, And A Number Of Other Nations.


Market Trend
  • Emergence of Advance Cell Therapy Procedures

Market Drivers
  • Rising R&D Investments in Cell-Based Research
  • Prevalence of Cancer and Chronic Diseases
  • Increasing Number of Oncology-Related Cell Therapy Clinical Trials

Opportunities
  • Growth in Healthcare Infrastructure and Expenditure

Restraints
  • Low Success Rate Associated to R&D
  • High-Cost Expenses

Challenges
  • Market Penetration Across New Regions
  • Lack of Trained Professionals


Key Target Audience
Pharma & Biotech Manufactures, New Entrants and Investors, Pharma & Biotech Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Cellular Therapy in Oncology Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Consumables
  • Equipment (Cell Processing Equipment, Single-use Equipment)
  • Systems & Software
By Technology
  • Bioreactor
  • Cell Immortalization Technology
  • Controlflow centrifugation
  • Ultrasonic Lysis
  • Lyophilization
  • Electrodspinning
  • Viral Vector Technology
  • Genome Editing Technology

By End Use
  • Hospitals
  • Specialty Clinics

By Cell
  • T-cells
  • Stem Cells
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising R&D Investments in Cell-Based Research
      • 3.2.2. Prevalence of Cancer and Chronic Diseases
      • 3.2.3. Increasing Number of Oncology-Related Cell Therapy Clinical Trials
    • 3.3. Market Challenges
      • 3.3.1. Market Penetration Across New Regions
      • 3.3.2. Lack of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advance Cell Therapy Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cellular Therapy in Oncology, by Type, Technology, End Use, Cell and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cellular Therapy in Oncology (Value)
      • 5.2.1. Global Cellular Therapy in Oncology by: Type (Value)
        • 5.2.1.1. Consumables
        • 5.2.1.2. Equipment (Cell Processing Equipment, Single-use Equipment)
        • 5.2.1.3. Systems & Software
      • 5.2.2. Global Cellular Therapy in Oncology by: Technology (Value)
        • 5.2.2.1. Bioreactor
        • 5.2.2.2. Cell Immortalization Technology
        • 5.2.2.3. Controlflow centrifugation
        • 5.2.2.4. Ultrasonic Lysis
        • 5.2.2.5. Lyophilization
        • 5.2.2.6. Electrodspinning
        • 5.2.2.7. Viral Vector Technology
        • 5.2.2.8. Genome Editing Technology
      • 5.2.3. Global Cellular Therapy in Oncology by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
      • 5.2.4. Global Cellular Therapy in Oncology by: Cell (Value)
        • 5.2.4.1. T-cells
        • 5.2.4.2. Stem Cells
        • 5.2.4.3. Others
      • 5.2.5. Global Cellular Therapy in Oncology Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cellular Therapy in Oncology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. MaxCyte (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck KGaA (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Becton, Dickinson and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lonza Group (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius Medical Care AG & Co. KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Techne Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sartorius AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Terumo BCT (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cellular Therapy in Oncology Sale, by Type, Technology, End Use, Cell and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cellular Therapy in Oncology (Value)
      • 7.2.1. Global Cellular Therapy in Oncology by: Type (Value)
        • 7.2.1.1. Consumables
        • 7.2.1.2. Equipment (Cell Processing Equipment, Single-use Equipment)
        • 7.2.1.3. Systems & Software
      • 7.2.2. Global Cellular Therapy in Oncology by: Technology (Value)
        • 7.2.2.1. Bioreactor
        • 7.2.2.2. Cell Immortalization Technology
        • 7.2.2.3. Controlflow centrifugation
        • 7.2.2.4. Ultrasonic Lysis
        • 7.2.2.5. Lyophilization
        • 7.2.2.6. Electrodspinning
        • 7.2.2.7. Viral Vector Technology
        • 7.2.2.8. Genome Editing Technology
      • 7.2.3. Global Cellular Therapy in Oncology by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
      • 7.2.4. Global Cellular Therapy in Oncology by: Cell (Value)
        • 7.2.4.1. T-cells
        • 7.2.4.2. Stem Cells
        • 7.2.4.3. Others
      • 7.2.5. Global Cellular Therapy in Oncology Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cellular Therapy in Oncology: by Type(USD Million)
  • Table 2. Cellular Therapy in Oncology Consumables , by Region USD Million (2015-2020)
  • Table 3. Cellular Therapy in Oncology Equipment (Cell Processing Equipment, Single-use Equipment) , by Region USD Million (2015-2020)
  • Table 4. Cellular Therapy in Oncology Systems & Software , by Region USD Million (2015-2020)
  • Table 5. Cellular Therapy in Oncology: by Technology(USD Million)
  • Table 6. Cellular Therapy in Oncology Bioreactor , by Region USD Million (2015-2020)
  • Table 7. Cellular Therapy in Oncology Cell Immortalization Technology , by Region USD Million (2015-2020)
  • Table 8. Cellular Therapy in Oncology Controlflow centrifugation , by Region USD Million (2015-2020)
  • Table 9. Cellular Therapy in Oncology Ultrasonic Lysis , by Region USD Million (2015-2020)
  • Table 10. Cellular Therapy in Oncology Lyophilization , by Region USD Million (2015-2020)
  • Table 11. Cellular Therapy in Oncology Electrodspinning , by Region USD Million (2015-2020)
  • Table 12. Cellular Therapy in Oncology Viral Vector Technology , by Region USD Million (2015-2020)
  • Table 13. Cellular Therapy in Oncology Genome Editing Technology , by Region USD Million (2015-2020)
  • Table 14. Cellular Therapy in Oncology: by End Use(USD Million)
  • Table 15. Cellular Therapy in Oncology Hospitals , by Region USD Million (2015-2020)
  • Table 16. Cellular Therapy in Oncology Specialty Clinics , by Region USD Million (2015-2020)
  • Table 17. Cellular Therapy in Oncology: by Cell(USD Million)
  • Table 18. Cellular Therapy in Oncology T-cells , by Region USD Million (2015-2020)
  • Table 19. Cellular Therapy in Oncology Stem Cells , by Region USD Million (2015-2020)
  • Table 20. Cellular Therapy in Oncology Others , by Region USD Million (2015-2020)
  • Table 21. South America Cellular Therapy in Oncology, by Country USD Million (2015-2020)
  • Table 22. South America Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 23. South America Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 24. South America Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 25. South America Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 26. Brazil Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 27. Brazil Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 28. Brazil Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 29. Brazil Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 30. Argentina Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 31. Argentina Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 32. Argentina Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 33. Argentina Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 34. Rest of South America Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 36. Rest of South America Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 37. Rest of South America Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 38. Asia Pacific Cellular Therapy in Oncology, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 41. Asia Pacific Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 42. Asia Pacific Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 43. China Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 44. China Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 45. China Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 46. China Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 47. Japan Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 48. Japan Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 49. Japan Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 50. Japan Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 51. India Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 52. India Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 53. India Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 54. India Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 55. South Korea Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 56. South Korea Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 57. South Korea Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 58. South Korea Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 59. Taiwan Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 60. Taiwan Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 61. Taiwan Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 62. Taiwan Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 63. Australia Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 64. Australia Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 65. Australia Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 66. Australia Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 71. Europe Cellular Therapy in Oncology, by Country USD Million (2015-2020)
  • Table 72. Europe Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 73. Europe Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 74. Europe Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 75. Europe Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 76. Germany Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 77. Germany Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 78. Germany Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 79. Germany Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 80. France Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 81. France Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 82. France Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 83. France Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 84. Italy Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 85. Italy Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 86. Italy Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 87. Italy Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 88. United Kingdom Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 90. United Kingdom Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 91. United Kingdom Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 92. Netherlands Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 93. Netherlands Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 94. Netherlands Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 95. Netherlands Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 96. Rest of Europe Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 98. Rest of Europe Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 99. Rest of Europe Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 100. MEA Cellular Therapy in Oncology, by Country USD Million (2015-2020)
  • Table 101. MEA Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 102. MEA Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 103. MEA Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 104. MEA Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 105. Middle East Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 106. Middle East Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 107. Middle East Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 108. Middle East Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 109. Africa Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 110. Africa Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 111. Africa Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 112. Africa Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 113. North America Cellular Therapy in Oncology, by Country USD Million (2015-2020)
  • Table 114. North America Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 115. North America Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 116. North America Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 117. North America Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 118. United States Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 119. United States Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 120. United States Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 121. United States Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 122. Canada Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 123. Canada Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 124. Canada Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 125. Canada Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 126. Mexico Cellular Therapy in Oncology, by Type USD Million (2015-2020)
  • Table 127. Mexico Cellular Therapy in Oncology, by Technology USD Million (2015-2020)
  • Table 128. Mexico Cellular Therapy in Oncology, by End Use USD Million (2015-2020)
  • Table 129. Mexico Cellular Therapy in Oncology, by Cell USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Cellular Therapy in Oncology: by Type(USD Million)
  • Table 141. Cellular Therapy in Oncology Consumables , by Region USD Million (2021-2026)
  • Table 142. Cellular Therapy in Oncology Equipment (Cell Processing Equipment, Single-use Equipment) , by Region USD Million (2021-2026)
  • Table 143. Cellular Therapy in Oncology Systems & Software , by Region USD Million (2021-2026)
  • Table 144. Cellular Therapy in Oncology: by Technology(USD Million)
  • Table 145. Cellular Therapy in Oncology Bioreactor , by Region USD Million (2021-2026)
  • Table 146. Cellular Therapy in Oncology Cell Immortalization Technology , by Region USD Million (2021-2026)
  • Table 147. Cellular Therapy in Oncology Controlflow centrifugation , by Region USD Million (2021-2026)
  • Table 148. Cellular Therapy in Oncology Ultrasonic Lysis , by Region USD Million (2021-2026)
  • Table 149. Cellular Therapy in Oncology Lyophilization , by Region USD Million (2021-2026)
  • Table 150. Cellular Therapy in Oncology Electrodspinning , by Region USD Million (2021-2026)
  • Table 151. Cellular Therapy in Oncology Viral Vector Technology , by Region USD Million (2021-2026)
  • Table 152. Cellular Therapy in Oncology Genome Editing Technology , by Region USD Million (2021-2026)
  • Table 153. Cellular Therapy in Oncology: by End Use(USD Million)
  • Table 154. Cellular Therapy in Oncology Hospitals , by Region USD Million (2021-2026)
  • Table 155. Cellular Therapy in Oncology Specialty Clinics , by Region USD Million (2021-2026)
  • Table 156. Cellular Therapy in Oncology: by Cell(USD Million)
  • Table 157. Cellular Therapy in Oncology T-cells , by Region USD Million (2021-2026)
  • Table 158. Cellular Therapy in Oncology Stem Cells , by Region USD Million (2021-2026)
  • Table 159. Cellular Therapy in Oncology Others , by Region USD Million (2021-2026)
  • Table 160. South America Cellular Therapy in Oncology, by Country USD Million (2021-2026)
  • Table 161. South America Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 162. South America Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 163. South America Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 164. South America Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 165. Brazil Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 166. Brazil Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 167. Brazil Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 168. Brazil Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 169. Argentina Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 170. Argentina Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 171. Argentina Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 172. Argentina Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 173. Rest of South America Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 174. Rest of South America Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 175. Rest of South America Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 176. Rest of South America Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 177. Asia Pacific Cellular Therapy in Oncology, by Country USD Million (2021-2026)
  • Table 178. Asia Pacific Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 179. Asia Pacific Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 180. Asia Pacific Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 181. Asia Pacific Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 182. China Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 183. China Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 184. China Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 185. China Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 186. Japan Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 187. Japan Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 188. Japan Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 189. Japan Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 190. India Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 191. India Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 192. India Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 193. India Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 194. South Korea Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 195. South Korea Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 196. South Korea Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 197. South Korea Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 198. Taiwan Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 199. Taiwan Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 200. Taiwan Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 201. Taiwan Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 202. Australia Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 203. Australia Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 204. Australia Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 205. Australia Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 210. Europe Cellular Therapy in Oncology, by Country USD Million (2021-2026)
  • Table 211. Europe Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 212. Europe Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 213. Europe Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 214. Europe Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 215. Germany Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 216. Germany Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 217. Germany Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 218. Germany Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 219. France Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 220. France Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 221. France Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 222. France Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 223. Italy Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 224. Italy Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 225. Italy Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 226. Italy Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 227. United Kingdom Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 228. United Kingdom Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 229. United Kingdom Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 230. United Kingdom Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 231. Netherlands Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 232. Netherlands Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 233. Netherlands Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 234. Netherlands Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 235. Rest of Europe Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 236. Rest of Europe Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 237. Rest of Europe Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 238. Rest of Europe Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 239. MEA Cellular Therapy in Oncology, by Country USD Million (2021-2026)
  • Table 240. MEA Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 241. MEA Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 242. MEA Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 243. MEA Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 244. Middle East Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 245. Middle East Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 246. Middle East Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 247. Middle East Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 248. Africa Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 249. Africa Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 250. Africa Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 251. Africa Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 252. North America Cellular Therapy in Oncology, by Country USD Million (2021-2026)
  • Table 253. North America Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 254. North America Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 255. North America Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 256. North America Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 257. United States Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 258. United States Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 259. United States Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 260. United States Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 261. Canada Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 262. Canada Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 263. Canada Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 264. Canada Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 265. Mexico Cellular Therapy in Oncology, by Type USD Million (2021-2026)
  • Table 266. Mexico Cellular Therapy in Oncology, by Technology USD Million (2021-2026)
  • Table 267. Mexico Cellular Therapy in Oncology, by End Use USD Million (2021-2026)
  • Table 268. Mexico Cellular Therapy in Oncology, by Cell USD Million (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cellular Therapy in Oncology: by Type USD Million (2015-2020)
  • Figure 5. Global Cellular Therapy in Oncology: by Technology USD Million (2015-2020)
  • Figure 6. Global Cellular Therapy in Oncology: by End Use USD Million (2015-2020)
  • Figure 7. Global Cellular Therapy in Oncology: by Cell USD Million (2015-2020)
  • Figure 8. South America Cellular Therapy in Oncology Share (%), by Country
  • Figure 9. Asia Pacific Cellular Therapy in Oncology Share (%), by Country
  • Figure 10. Europe Cellular Therapy in Oncology Share (%), by Country
  • Figure 11. MEA Cellular Therapy in Oncology Share (%), by Country
  • Figure 12. North America Cellular Therapy in Oncology Share (%), by Country
  • Figure 13. Global Cellular Therapy in Oncology share by Players 2020 (%)
  • Figure 14. Global Cellular Therapy in Oncology share by Players (Top 3) 2020(%)
  • Figure 15. Global Cellular Therapy in Oncology share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 19. MaxCyte (United States) Revenue, Net Income and Gross profit
  • Figure 20. MaxCyte (United States) Revenue: by Geography 2020
  • Figure 21. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Danaher Corporation (United States) Revenue: by Geography 2020
  • Figure 23. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 25. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Becton, Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 27. Lonza Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Lonza Group (Switzerland) Revenue: by Geography 2020
  • Figure 29. Fresenius Medical Care AG & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Fresenius Medical Care AG & Co. KGaA (Germany) Revenue: by Geography 2020
  • Figure 31. Bio-Techne Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bio-Techne Corporation (United States) Revenue: by Geography 2020
  • Figure 33. Sartorius AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Sartorius AG (Germany) Revenue: by Geography 2020
  • Figure 35. Terumo BCT (United States) Revenue, Net Income and Gross profit
  • Figure 36. Terumo BCT (United States) Revenue: by Geography 2020
  • Figure 37. Global Cellular Therapy in Oncology: by Type USD Million (2021-2026)
  • Figure 38. Global Cellular Therapy in Oncology: by Technology USD Million (2021-2026)
  • Figure 39. Global Cellular Therapy in Oncology: by End Use USD Million (2021-2026)
  • Figure 40. Global Cellular Therapy in Oncology: by Cell USD Million (2021-2026)
  • Figure 41. South America Cellular Therapy in Oncology Share (%), by Country
  • Figure 42. Asia Pacific Cellular Therapy in Oncology Share (%), by Country
  • Figure 43. Europe Cellular Therapy in Oncology Share (%), by Country
  • Figure 44. MEA Cellular Therapy in Oncology Share (%), by Country
  • Figure 45. North America Cellular Therapy in Oncology Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific Inc. (United States)
  • MaxCyte (United States)
  • Danaher Corporation (United States)
  • Merck KGaA (Germany)
  • Becton, Dickinson and Company (United States)
  • Lonza Group (Switzerland)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Bio-Techne Corporation (United States)
  • Sartorius AG (Germany)
  • Terumo BCT (United States)
Additional players considered in the study are as follows:
Avantor, Inc. (United States) , RoosterBio Inc. (United States) , SIRION Biotech GmbH (Germany) , CellGenix GmbH (Germany) , Miltenyi Biotec GmbH (Germany) , STEMCELL Technologies (Canada) , IxCells Biotechnology (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation